Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00494507 · ClinicalTrials.gov registry record · Phase 3
Hyper- and Hypokalemic Periodic Paralysis Study
A Phase 3 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT00494507: Completed Phase 3 study, sponsored by University of Rochester.
NCT00494507 is a Phase 3 study that has completed, run by University of Rochester. The registered enrollment target is 71 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00494507, a Phase 3 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.
Primary Outcome
The number of distinct attacks per week over the final 8 weeks (Weeks 2-9) of the double-blind treatment period as self-reported by HYP participants.
Interventions
- DRUG Dichlorphenamide (double-blind)
- DRUG Placebo (double-blind)
- DRUG Dichlorphenamide (open-label)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT00494507 record still lists
NCT00494507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Dichlorphenamide (double-blind) is the first listed.
NCT00494507 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00494507 about?
NCT00494507 is a clinical study titled "Hyper- and Hypokalemic Periodic Paralysis Study". The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic ...
What is the current status of trial NCT00494507?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2007-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00494507?
The interventions under investigation include: Dichlorphenamide (double-blind) (DRUG), Placebo (double-blind) (DRUG), Dichlorphenamide (open-label) (DRUG).
Who is sponsoring clinical trial NCT00494507?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00494507's enrollment target sits among peer trials
71 1784th of 2000 higher than 216 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia